ANDROGEN-ESTROGEN BALANCE AND LIPID METABOLISM IN MEN WITH TYPE 2 DIABETES

Pustovoyt H. L.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The study of aging has an important place in modern medicine, as it is associated with an increase in life expectancy and, consequently, the number of aging people. The criterion of age-related changes of the population is life expectancy, which is calculated for each definite country. Life expectancy in Ukraine ranks 143 place in the world, mortality occupies first place. The main sex hormone, which determines gender identity and various aspects of the male body is testosterone. As it known, the main precursor for testosterone is cholesterol, and on earlier stages is glucose. The aim of study was to evaluate the androgen-estrogen balance and lipid metabolism in men of different age groups, patients with type 2 diabetes combined with hypertension. The study involved 88 men aged 45 to 76 years. All patients were divided into two groups according to age. Fifty study participants had a history of type 2 diabetes combined with hypertension and entered the main group of the appropriate age. The control group included 38 men who did not have the above-mentioned diseases. First group (I) consisted of 42 middle-aged men (45-59 years). Second group (II) included 46 males aged 60 years or more. According to a study design in patients of first age group suffering from type 2 diabetes combined with hypertension moderate hypertriglyceridemia was revealed, whereas in second age group, the levels were much higher. Atherogenic ratio was significantly higher (p<0.05) in patients of second age group compared with persons of the first age group. According to our records in patients with type 2 diabetes combined with hypertension significantly worsening lipid metabolism was observed, which can lead to progressing of atherosclerosis and development of severe complications such as coronary heart disease, myocardial infarction, stroke, obliterating arterial disease. During the study the decrease of total testosterone in patients with type 2 diabetes II age group was determined. Free testosterone level was almost twice reduced according to the main subgroups of the elder patients. At the same time estradiol levels were increased in both age groups of patients with type 2 diabetes complicated with hypertension. One reason for the decrease of total and free testosterone levels in diabetic patients is deterioration of blood supply as a result of testicular tissue angiopathy. Therefore, the treatment of age-related androgen deficiency in patients with type 2 diabetes must include drugs that improve microcirculation. In order to reduce cardiovascular risk normalization of lipid metabolism in the above-mentioned category of patients is required, which will also have a positive effect on testicular tissue and androgenic status of patients.

type 2 diabetes, lipid metabolism, male androgen deficiency

• 1. Анисимов В.И. Приоритетные направления фундаментальных исследований в геронтологии: вклад России / В.И. Анисимов // Успехи геронтологии. – 2003. – Т. 12. – С. 9-27.
• 2. Анисимов В.Н. Молекулярные и физиологические механизмы старения / В.Н. Анисимов // СПб : Издательский дом наука, 2008. – Т. 2. – 434 с.
• 3. Асінова М. Майже кожна людина старіє передчасно / М. Асінова // Медицина і здоров’я. — 2008. — № 34-35. — С. 2.
• 4. Березов Т.Т. Биологическая химия: учебник / Т.Т. Березов, Б.Ф Коровкин // М.: Медицина, 1998. — С. 704.
• 5. Верткин А.Л. Возрастной гипогонадизм у пациентов в клинике внутренних болезней / А.Л. Верткин, Е.Н. Аринина [и др.] // Материалы Международного конгресса по андрологии, 24-26 мая 2006, Сочи, С. 10-11.
• 6. Гвасалия Б.Р. Поздний гипогонадизм, метаболический синдром и сердечно–сосудистая патология / Б.Р. Гвасалия, П.А. Щеплев // Лечащий врач. – 2009. – № 11. – C. 4-8.
• 7. Горпинченко И.И. Гормонотерапия половых расстройств и другие методы медикаментозного лечения / И.И. Горпинченко, Л.П. Имшенецкая // К.: Космополис, 2004. – 48 с.
• 8. Дильман В.М. Четыре модели медицины / В.М. Дильман // М.: Медицина, 1987. – 288 с.
• 9. Коробейніков Г.В. Біологічні механізми старіння і рухова активність людини / Г.В. Коробейніков // Фізична активність, здоровʼя і спорт. – 2010. — № 2. – С. 3-13.
• 10. Моргунов Л.Ю. Воздействие тестостерона на факторы риска ишемической болезни сердца у пациентов с андрогенным дефицитом / Л.Ю. Моргунов // Материалы II Съезда кардиологов Сибирского федерального округа. Томск, 6-7 июня 2007. — С. 86.
• 11. Моргунов Л.Ю. Возрастной андрогендефицит и сердечно-сосудистая патология / Л.Ю. Моргунов // «Клинико-лабораторный консилиум». — 2006. — № 13. — С. 34-39.
• 12. Col V. New insights into insulin resistance pathophysiology: how it affects glucose and lipid metabolism / V. Col // Acta clinica Belgica. – 2000. – Vol. 56 (3). – P. 155-162.
• 13. Harman S. M. Adverse events observed in healthy women and men over 65 years of age treated with GH and sex steroid hormone replacement (fbstract 1635) / S.M. Harman, K.M Pabst, T. Munzer [et al.] // In Programs and Abstracts of Endocrine Society Annual Meeting. — Toronto, 2000. — Р. 394.
• 14. Svartberg J. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study / J. Svartberg, T. Jenssen, J. Sundsfjord [et al.] // Eur J Endocrinol. – 2004. — V. 150 (1). — P. 65-71.
• 15. The metabolic syndrome and cardiovascular disease mortality in middle–aged men / H.–M. Lakka, D.E. Laaksonen, T.A. Lakka [et al.] // JAMA. – 2002. – Vol. 283. – P. 2909-2916.
• 16. Von Eckardstein A. Testosterone and atherosclerosis / Von A. Eckardstein, F.C.W. Wu // Growth hormone & IGF research. – 2003. – Vol. 13. – P. 72-84.

«Bulletin of problems biology and medicine» Issue 2 part 1 (128), 2016 year, 87-89 pages, index UDK 616.379 – 008.64